PCSA实时信号 | 通过Getagraph.com最大化利润

购买 110541 min ago

@ $2.43

发出时间: 13 Feb 2024 @ 04:26

回报率: -12.76%

上一信号: Feb 7 - 03:26

上一信号: 出售

回报率: 0.00 %

Live Chart Being Loaded With Signals

Commentary (29 Apr 2024 @ 22:47):

Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States...

Stats
今日成交量	123 928
平均成交量	1.52M
市值	6.05M
EPS	$0 ( 2024-04-04 )
下一个收益日期	( $0 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.250
ATR14	$0.0260 (1.22%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-01	Young David	Buy	1 675	Common Stock
2024-01-01	Young David	Sell	518	Common Stock
2024-01-01	Young David	Sell	1 675	Restricted Stock Units
2024-01-01	Stanker James H	Sell	1 675	Restricted Stock Units
2024-01-01	Stanker James H	Buy	1 675	Common Stock

INSIDER POWER
80.29
Last 99 transactions
Buy: 3 005 145 \| Sell: 402 801

音量相关性

長: -0.03 (neutral)

短: -0.01 (neutral)

Signal:(54.151) Neutral

Processa Pharmaceuticals, 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Processa Pharmaceuticals, 相关性 - 货币/商品

-0.03
( neutral )

-0.10
( neutral )

0.00
( neutral )

-0.11
( neutral )

0.43
( neutral )

0.14
( neutral )

Processa Pharmaceuticals, 财务报表

Annual	2023
营收:	$0
毛利润:	$-222.00 (0.00 %)
EPS:	$-8.48

FY	2023
营收:	$0
毛利润:	$-222.00 (0.00 %)
EPS:	$-8.48

FY	2022
营收:	$0
毛利润:	$-27.53M (0.00 %)
EPS:	$-68.10

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-0.750

Financial Reports:

No articles found.

Processa Pharmaceuticals,

Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet that is in Phase 2B clinical trials for the treatment of ulcerative and non-ulcerative necrobiosis lipoidica, a chronic disfiguring condition. The company is also developing PCS12852, a novel selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist that is in Phase 2A clinical trials for the treatment of gastroparesis, chronic constipation, constipation-predominant irritable bowel syndrome, and functional dyspepsia; PCS3117, a cytosine analog, which is in Phase 2B clinical trials for the treatment of pancreatic and non-small cell lung cancer; and PCS6422, an oral, potent, selective, and irreversible inhibitor of dihydropyrimidine dehydrogenase that is in Phase 1B clinical trials for treating metastatic colorectal and breast cancer. In addition, it develops PCS11T, an analog of SN38 and irinotecan drug for the treatment of various cancers. The company was incorporated in 2011 and is based in Hanover, Maryland.